88
Mediwound Ltd. Has announced that the Australian Therapeutic Goods Administration (TGA) granted the market approval for Nexobrid®. This is the innovative enzymatic therapy of the company to remove scab in adults and pediatric patients with depths, partial and complete thermal burns. With this approval, Nexobrid is now authorized in 45 countries worldwide, which underlines increasing recognition as a new treatment standard in internal combustion management. Mediwound’s exclusive partner in Australia, Balance Medical, is planning the commercial start in the fourth quarter of 2025.
The manufacturing extension of Mediwound, whose degree is scheduled until the end of 2025, will support this market start and future worldwide demand.
